Last reviewed · How we verify
IM-101 Part B
At a glance
| Generic name | IM-101 Part B |
|---|---|
| Sponsor | ImmunAbs Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IM-101 Part B CI brief — competitive landscape report
- IM-101 Part B updates RSS · CI watch RSS
- ImmunAbs Inc. portfolio CI